文献速递心脑血管急症

经皮冠状动脉成形术与冠状动脉旁路移植术治疗无保护左主干狭窄:随机非劣效性NOBLE试验的5年更新结果

Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
PubMed 文献 · Lancet · 2019-12-23
一句话结论在无保护左主干病变血运重建中,5年随访时PCI的主要不良心脑血管事件显著劣于CABG,CABG在主要复合终点上优于PCI。

NOBLE试验是一项前瞻性、随机、开放标签、非劣效性试验,在9个北欧国家的36家医院纳入需血运重建的左主干冠状动脉疾病患者1201例,按1:1随机分配至PCI组(n=598)或CABG组(n=603),主要终点为主要不良心脑血管事件(MACCE,包括全因死亡、非操作性心肌梗死、再次血运重建和卒中)的复合终点。中位随访4.9年时,PCI组5年MACCE发生率为28%(165例事件),CABG组为19%(110例事件),HR 1.58(95%CI 1.24-2.01),其置信区间上限超过预设的非劣效界值1.35,CABG在主要复合终点上优于PCI(p=0.0002)。全因死亡率两组相似(9% vs 9%,HR 1.08,95%CI 0.74-1.59,p=0.68),但PCI组非操作性心肌梗死(8% vs 3%,HR 2.99,95%CI 1.66-5.39,p=0.0002)和再次血运重建(17% vs 10%,HR 1.73,95%CI 1.25-2.40,p=0.0009)发生率更高。

要点

  • 在无保护左主干病变患者中,5年MACCE发生率PCI组28% vs CABG组19%(HR 1.58,95%CI 1.24-2.01),超过非劣效界值1.35,CABG在主要复合终点上优于PCI(p=0.0002)。
  • 全因死亡率PCI组9% vs CABG组9%(HR 1.08,95%CI 0.74-1.59,p=0.68),两组无显著差异。
  • 非操作性心肌梗死PCI组8% vs CABG组3%(HR 2.99,95%CI 1.66-5.39,p=0.0002),PCI组更高。
  • 再次血运重建PCI组17% vs CABG组10%(HR 1.73,95%CI 1.25-2.40,p=0.0009),PCI组更高。
  • 中位随访4.9年时达到预设事件数,结果支持在左主干血运重建中CABG优于PCI。

适用人群与场景

  • 需血运重建的左主干冠状动脉疾病患者,来自9个北欧国家的36家医院,随机分配至PCI或CABG。

诊断标准与关键阈值

  • 非劣效性界值:PCI对比CABG的风险比95%CI上限不超过1.35,在发生275例MACCE后评估。

研究设计与关键结果

  • 研究类型:前瞻性、随机、开放标签、非劣效性试验(NOBLE),36家医院,纳入1201例患者,PCI组598例、CABG组603例,每组592例纳入分析(意向性治疗人群)。
  • 主要终点:5年MACCE发生率PCI组28%(165例事件) vs CABG组19%(110例事件),HR 1.58(95%CI 1.24-2.01),超过非劣效界值,CABG优于PCI(p=0.0002)。
  • 全因死亡率:PCI组9% vs CABG组9%,HR 1.08(95%CI 0.74-1.59),p=0.68,无显著差异。
  • 非操作性心肌梗死:PCI组8% vs CABG组3%,HR 2.99(95%CI 1.66-5.39),p=0.0002。
  • 再次血运重建:PCI组17% vs CABG组10%,HR 1.73(95%CI 1.25-2.40),p=0.0009。

证据类型、等级与局限

  • 证据类型:随机对照试验(非劣效性设计),意向性治疗分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在无保护左主干病变血运重建决策中,5年随访数据表明PCI的主要不良心脑血管事件复合终点劣于CABG,CABG在主要复合终点上优于PCI。
  • PCI与CABG的全因死亡率相似,但PCI与非操作性心肌梗死和再次血运重建率更高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Percutaneous coronary intervention (PCI) is increasingly used in revascularisation of patients with left main coronary artery disease in place of the standard treatment, coronary artery bypass grafting (CABG). The NOBLE trial aimed to evaluate whether PCI was non-inferior to CABG in the treatment of left main coronary artery disease and reported outcomes after a median follow-up of 3·1 years. We now report updated 5-year outcomes of the trial.

METHODS: The prospective, randomised, open-label, non-inferiority NOBLE trial was done at 36 hospitals in nine northern European countries. Patients with left main coronary artery disease requiring revascularisation were enrolled and randomly assigned (1:1) to receive PCI or CABG. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause mortality, non-procedural myocardial infarction, repeat revascularisation, and stroke. Non-inferiority of PCI to CABG was defined as the upper limit of the 95% CI of the hazard ratio (HR) not exceeding 1·35 after 275 MACCE had occurred. Secondary endpoints included all-cause mortality, non-procedural myocardial infarction, and repeat revascularisation. Outcomes were analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT01496651.

FINDINGS: Between Dec 9, 2008, and Jan 21, 2015, 1201 patients were enrolled and allocated to PCI (n=598) or CABG (n=603), with 17 subsequently lost to early follow-up. 592 patients in each group were included in this analysis. At a median of 4·9 years of follow-up, the predefined number of events was reached for adequate power to assess the primary endpoint. Kaplan-Meier 5-year estimates of MACCE were 28% (165 events) for PCI and 19% (110 events) for CABG (HR 1·58 [95% CI 1·24-2·01]); the HR exceeded the limit for non-inferiority of PCI compared to CABG. CABG was found to be superior to PCI for the primary composite endpoint (p=0·0002). All-cause mortality was estimated in 9% after PCI versus 9% after CABG (HR 1·08 [95% CI 0·74-1·59]; p=0·68); non-procedural myocardial infarction was estimated in 8% after PCI versus 3% after CABG (HR 2·99 [95% CI 1·66-5·39]; p=0·0002); and repeat revascularisation was estimated in 17% after PCI versus 10% after CABG (HR 1·73 [95% CI 1·25-2·40]; p=0·0009).

INTERPRETATION: In revascularisation of left main coronary artery disease, PCI was associated with an inferior clinical outcome at 5 years compared with CABG. Mortality was similar after the two procedures but patients treated with PCI had higher rates of non-procedural myocardial infarction and repeat revascularisation.

FUNDING: Biosensors.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2019. PMID: 31879028. doi:10.1016/S0140-6736(19)32972-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。